FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Verrica Pharmaceuticals Inc. - Common Stock
(NQ:
VRCA
)
4.380
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verrica Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
September 30, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
September 10, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 08, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
August 27, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica (VRCA) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
YCANTH dispensed units surged 28% sequentially as the company secured $27.5M in financing.
Via
The Motley Fool
Topics
Earnings
Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum
↗
May 12, 2026
Via
Chartmill
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Reports Q4 Earnings Beat and Accelerating Revenue Growth
↗
March 11, 2026
Via
Chartmill
Topics
Earnings
Verrica Pharmaceuticals Q2 Earnings Call Highlights
↗
August 07, 2026
Verrica Pharmaceuticals (NASDAQ:VRCA) reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common...
Via
MarketBeat
Topics
Earnings
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 06, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
August 06, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
July 30, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
July 21, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
June 22, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 28, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica (VRCA) Q1 2026 Earnings Transcript
↗
May 13, 2026
Verrica (VRCA) Q1 2026 Earnings Transcript
Via
The Motley Fool
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Q1 Earnings Call Highlights
↗
May 12, 2026
Verrica Pharmaceuticals (NASDAQ:VRCA) reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs...
Via
MarketBeat
Topics
Earnings
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
May 12, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
May 05, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
May 05, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
April 09, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 06, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
March 20, 2026
From
The Schall Law Firm
Via
Business Wire
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
March 20, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
March 19, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 11, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
March 05, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
February 23, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
February 12, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
February 09, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
